Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies
Phase 1 Terminated
1 enrolled
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Phase 2 Terminated
31 enrolled 18 charts
Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps
Phase 1/2 Terminated
8 enrolled 8 charts
Cord Blood Transplant With Dilanubicel for the Treatment of HIV Positive Hematologic Cancers
Phase 2 Terminated
1 enrolled 11 charts
Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Terminated
20 enrolled 8 charts
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Terminated
46 enrolled 18 charts
BMT CTN 0202
Phase 2/3 Terminated
30 enrolled 5 charts
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma
Phase 1 Terminated
2 enrolled 14 charts
High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Phase 2 Terminated
20 enrolled 15 charts
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Phase 2 Terminated
342 enrolled 14 charts
THALLO
Phase NA Terminated
10 enrolled 15 charts
Early or Delayed Fludarabine and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia
Phase 3 Terminated
84 enrolled 10 charts
Study Of Two Non-Myeloablative Stem Cell Transplant Strategies For Low-Grade Lymphoma And CLL
Phase 2 Terminated
10 enrolled
Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)
Phase 2 Terminated
39 enrolled 10 charts
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Phase NA Terminated
2 enrolled 11 charts
Post Transplant Donor Lymphocyte Infusion
Phase 2 Terminated
57 enrolled 13 charts
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
Phase 1/2 Terminated
3 enrolled 15 charts
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Phase 1/2 Terminated
1 enrolled 8 charts
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
Phase 2 Terminated
442 enrolled 17 charts
Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor
Phase NA Terminated
3 enrolled 7 charts
Reduced-intensity, Related-donor Bone Marrow Transplantation Followed by High-dose Cyclophosphamide for Hematologic Cancers
Phase 2 Terminated
15 enrolled 8 charts
Donor Natural Killer Cell Infusion, Rituximab, Aldesleukin, and Chemotherapy in Treating Patients With Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Phase 1/2 Terminated
6 enrolled 10 charts
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Phase 1/2 Terminated
31 enrolled 24 charts
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Phase 1 Terminated
3 enrolled
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Phase 2 Terminated
13 enrolled 24 charts
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
Phase 2 Terminated
12 enrolled 12 charts
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
Phase 2 Terminated
1 enrolled 5 charts
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
Phase NA Terminated
16 enrolled 6 charts
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
Phase NA Terminated
6 enrolled 13 charts
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
Phase 2 Terminated
36 enrolled 16 charts
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia
Phase 1 Terminated
28 enrolled
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
Phase NA Terminated
8 enrolled
FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin's Lymphoma
Phase 2 Terminated
60 enrolled
Thalidomide With or Without Fludarabine in Treating Patients With Hematologic Cancer
Phase 2 Terminated
70 enrolled
EL625 in Persistent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Terminated
20 enrolled 9 charts
Combination Chemotherapy in Treating Children With Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 2 Terminated
13 enrolled
Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab
Phase 2 Terminated
15 enrolled 5 charts
S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma
Phase 2 Terminated
1 enrolled 6 charts
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Phase 2 Terminated
5 enrolled 5 charts
Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for Indolent Lymphoid Malignancies
Phase 1 Terminated
4 enrolled
Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma
Phase 2 Terminated
27 enrolled 5 charts